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Keyhole limpet haemocyanin (KLH) appears to be a promising protein carrier for tumor antigens in numerous cancer vaccine
candidates. The humoral immune response to KLH was characterized at the single-cell level with ELISPOT combined with
separationsofcellpopulationsaccordingtotheirexpressionofhomingreceptors (HRs).TheanalysisofHRexpressionsisexpected
to reveal the targeting of the immune response in the body. Eight orally primed and four nonprimed volunteers received KLH-
vaccine subcutaneously. Circulating KLH-speciﬁc plasmablasts were found in all volunteers, 60 KLH-speciﬁc plasmablasts/106
PBMC in the nonprimed and 136/106 in the primed group. The proportion of L-selectin+ plasmablasts proved high and integrin
α4β7
+ low. KLH serving as protein carrier in several vaccines, the homing proﬁle of KLH-speciﬁc response may be applicable to
the cancer antigen parts in the same vaccines. The present data reﬂect a systemic homing proﬁle, which appears advantageous for
the targeting of immune response to cancer vaccines.
1.Introduction
Manyimportant antigens, whether ofcancerousormicrobial
origin, are poorly immunogenic when injected into humans
in a soluble form. However, it is possible to signiﬁcantly
improve their immunogenicity by conjugation to a highly
immunogenic protein carrier such as tetanus toxoid (TT) or
keyhole limpet haemocyanin (KLH) [1, 2]. This conjugation
ensures that the robust T-cell help elicited by the carrier
protein is concentrated in the vicinity of T- and B-cells
speciﬁc to the weak antigen to which the protein carrier
is linked. This in turn facilitates the T-B cell cooperation
and results in a more vigorous immune response to the
weak antigen [2]. This approach has proved highly successful
in vaccines containing bacterial polysaccharides conjugated
to a protein carrier [1]: pneumococcal and Haemophilus
inﬂuenzae type b—TT conjugate vaccines, for example,
are used widely and have been introduced into national
vaccination programmes in several countries. Numerous
cancer antigens have been linked with KLH, resulting in
promising anticancer vaccine candidates [2–7].
KLH is a naturally occurring immunoadjuvant function-
ing as a respiratory protein of giant keyhole limpets living
in shallow coastal waters in a sea [8, 9]. It is a mixture of
two immunologically distinct isoforms, both of which are
didecamers assembled from 400 kDa polypeptides; an atom-
istic model of the quaternary structure of isoform KLH1 is
available [8]. This antigen is ordinarily not encountered by
the human immune system. KLH has been used in studies
addressing the phenomenon of oral tolerance; prolonged
oral priming with soluble KLH has been shown to result
in a suppression of T- cell-mediated immunity and delayed
hypersensitivity reaction after a subsequent subcutaneous
immunization [10, 11]. In contrast to this, the humoral2 Clinical and Developmental Immunology
immune response at both mucosal and systemic sites has
provedtobeenhanced[10].Thesestudieswerecarriedoutto
provide tools for eliciting oral tolerance useful in numerous
autoimmune diseases.
In addition to the tolerance studies, KLH has been
explored in cancer research. Originally, it was found to
be cross-reactive with cancer antigens in urinary bladder
carcinoma, which led to research into the use of KLH as
bladder carcinoma vaccine [2, 9]. More recently, however,
KLH has proved successful as a protein carrier to numerous
poorly immunogenic cancer antigens such as in vaccines
against follicular lymphoma [3], non-Hodgkin lymphoma
[6], glioblastoma multiforme [4], melanoma [2], prostate,
andovarian cancer[2].Theconjugatecancervaccinesappear
as the most extensively studied application of KLH at the
moment.
Immuneresponse tovaccinationisnotdistributedevenly
in the body, but, instead, activated lymphocyte populations
are guided to traﬃc only to certain tissues [12, 13]. Tissue-
speciﬁc migration is based on a multistep process of homing;
whilethebloodcarriestheactivatedlymphocyteseverywhere
in the body, the cellscan lodge into tissues only at sites which
they recognize by means of their speciﬁc surface molecules
[12, 13]. The most important molecules determining tissue
localization are chemokine (CCR) and homing receptors
(HRs) [12, 13], which recognize their ligands in the tissue,
chemokines, and endothelial addressins, respectively. Several
tissue-speciﬁc HRs have been identiﬁed; the intestinal HR,
α4β7 integrin, guides the cells to the intestinal mucosa [14],
L-selectin (CD62L) to peripheral lymph nodes [15, 16]a n d
cutaneous lymphocyte antigen (CLA) to cutaneous sites
[17, 18]. We have shown earlier that KLH-speciﬁc T-cells
after oral feeding express signiﬁcantly more α4β7 integrin
than KLH-speciﬁc T-cells after parenteral injection. Thus,
the homing proﬁle of KLH-speciﬁc T cells depends on the
site of antigen encounter [19]. With other antigens, the
homing proﬁle of B cells has been found to depend on the
site of antigen encounter [20–23]. The homing of B cells
after immunization with KLH has not been addressed in any
studies before.
The present study characterized at a single-cell level the
immune response to KLH and the homing proﬁles of these
cells. KLH being a common protein carrier to numerous
cancer antigens in various vaccines [2–7], this homing
proﬁle is of special interest, for it can be interpreted as the
homing proﬁle associated with all the diﬀerent injectable
cancer vaccines linked to KLH, and thus give an insight into
the localization of the response to these vaccines. Optimal
targeting of the ensuing immune response should always
be one of the goals of vaccine development. As to cancer
vaccines in general, it appears most beneﬁcial to target the
immune responses to the site where the primary tumor
developed.
2.Materialsand Methods
2.1. Volunteers. Fourteen healthy volunteers (8 women, 6
men, aged 22–40 years) participated in the study. None of
the volunteers had been previously exposed to KLH; all
of them had received TT vaccine according to the usual
vaccination protocol as a child and a booster dose within
the last ten years. The study was approved by the Human
UseCommitteeoftheUniversityofAlabamaatBirmingham.
Informed consent was obtained from each volunteer before
participation.
2.2. Experimental Design. Nine fasting volunteers ingested
each100mgofKLHondays1to5anddays15to19andwere
given100μgKLHsubcutaneouslyondays26and36(primed
group) (Figure 1(a)). Another 5 volunteers received only the
parenteral KLH on days 26 and 36 (nonprimed group).
Bloodsamplesweredrawnondays0,9,and44.Mononuclear
cells were isolated from the blood samples and subjected to
immunomagneticcellselectiontosortthecellsintoreceptor-
positive and-negative cell populations with respect to their
expression of α4β7 integrin and L-selectin (Figure 1(b)).
These populations were assayed for KLH- speciﬁc ASC with
enzyme-linked immunospot (ELISPOT) assay. Due to the
limited numbers of cells obtained, all assays could not be
carried out on all volunteers.
2.3.KLH. KLHasafreeze-dried powderwaspurchasedfrom
Calbiochem Corp. (La Jolla, CA, USA). For oral use, 100mg
of this preparation was packed into gelatin capsules. KLH
for parenteral use was purchased from Paciﬁc Biomarine
(Venice, CA, USA). It was puriﬁed from an ammonium
sulphate preparation of the protein. This preparation was
dissolved in pyrogen-free saline, passed twice through a
polymyxin-agarose column, and assayed for endotoxin con-
tent with Limulus assay as described in detail earlier [10].
2.4. Isolation of Mononuclear Cells. Mononuclear cells were
isolated with Ficoll-Paque density-gradient centrifugation
from heparinized venous blood. The cells were washed twice
with PBS and suspended in culture medium (RPMI-1640
supplemented with 10% heat inactivated fetal calf serum,
100U penicillin/mL and 100μgs t r e p t o m y c i n / m L )[ 19].
2.5.SeparationoftheReceptor-Negativeand-PositiveCellPop-
ulations. The separation of the cells into receptor-negative
and -positive populations has been described in detail
earlier [20, 22, 24]. Brieﬂy, cells were incubated with one
of the ﬁrst-stage monoclonal antibodies: anti-α4β7 (ACT-
1; Millennium Pharmaceuticals, Cambridge, MA, USA) or
anti-L-selectin (anti-CD62L; Becton-Dickinson, San Jose,
CA,USA).After washing the cells were incubated with Dynal
M-450 magnetic beads coated with sheep antimouse IgG
(Dynal,Oslo).Receptor-positiveand-negativecellsweresep-
arated with magnetic cell sorting. Both the receptor-positive
and -negative cell populations were immediately analyzed
with theELISPOTassay fornumbersofallimmunoglobulin-
secreting cells (ISC) and KLH-speciﬁc ASC. The eﬃciency
of the cell separations was checked with ﬂow cytometry in
pilot experiments as described earlier [20]; >90% of the L-
selectin+ cells including all brightly staining cells and >99%Clinical and Developmental Immunology 3
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Figure 1: Experimental design of the study. (a) Protocol for immunization with KLH and for collection of blood samples. The asterisks
indicate days ofcollecting blood samples.(b) AssayingKLH-speciﬁc circulating plasmablastsfrom the blood samples.The cells were assayed
both from the total population ofPBMC and from receptor-positive and -negative populations (a total of six separated populations for each
volunteer) resulting from immunomagnetic sorting with respect to diﬀerent HR.
of the integrin α4β7
+ cells were removed from the unsorted
cells by the negative selection.
2.6. Assay of ISC and ASC (ELISPOT). While ISC represents
all plasmablasts in the circulation, antigen-speciﬁc plas-
mablasts represent smaller subpopulations within the whole
populationofISC.KLH-speciﬁcplasmablastswere identiﬁed
as ASC speciﬁc for KLH. In the ELISPOT assay, plasmablasts
are allowed to secrete antibodies in the immediate vicinity of
the antigen (capturing Ig in ISC assays and antigen in ASC
assays) on a microwell plate, and the antibodies secreted are
then detected immunoenzymatically. The substrate is added
in hot agarose to immobilize the decaying colour into a spot.
Each spot is regarded to correspond to a single-cell secreting
antibodies speciﬁc to or captured by the coating antigen.
The assays of IgA-, IgG- and IgM-ISC/ASC [25]a n d
IgA1-and IgA2-ISC [26, 27] have been described in detail
previously. Brieﬂy, microtiter plates were coated with anti-
sera to human IgA or IgM (Dako, Glostrup, Denmark)
or IgG (Sigma, St. Louis, MO, USA) for the ISC-assay, or
with KLH (5μg/mL PBS) for the ASC assay and blocked
with 1% bovine serum albumin. The cells were incubated
in the wells for 2-3h, and antibodies secreted during this
time were detected with alkaline phosphatase-conjugated
antihuman IgA (Sigma-Aldrich), IgG (Sigma-Aldrich) and
IgM (SouthernBiotech, Birmingham, AL, USA) antisera or,
for the IgA-subclass assays, with monoclonal antibodies
to IgA1 and IgA2 (Nordic Immunological Laboratories,
Tilburg, the Netherlands) followed by alkaline phosphatase-
conjugated antimouse IgG (Jackson ImmunoResearch Lab-
oratories, West Grove, PA, USA). Substrate was added to all
plates in hot agarose as described in detail earlier [25].
2.7. Statistics. Percentages of cells expressing the diﬀerent
receptors were determined as arithmetic means of the
percentages of ISC expressing the given cell surface marker.
The proportions of the receptor-positive ISC were calculated
as follows: % of receptor-positive cells among ISC = (100 ×
the number of ASC or ISC in receptor-positive population)
÷ (the sum of the number of ASC or ISC in receptor-
positive and receptor-negative populations). In order to get
reliable statistics for the proportions of cells expressing a
givenmarker, we setan inclusionlimitof20ASCthatneeded
to be identiﬁed among the cells studied. Statistical analyses
were performed with Student’s t-test, and the results were
considered signiﬁcant only when P<. 05.
3.Results
3.1. Numbers of Total Ig-, IgA1-, and IgA2-Immunoglobulin-
Secreting Cells (ISC). The total populations of ISC represent
the sum of numerous antigen-speciﬁc populations of ASC.
On the average, 0.2% of peripheral blood mononuclear cells
(PBMC) were ISC (plasmablasts). The geometric mean of
IgA-ISC was 864, IgG-ISC 800 and IgM-ISC 89 cells/1064 Clinical and Developmental Immunology
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Figure 2: The numbers of KLH-speciﬁc plasmablasts identiﬁed
with ELISPOT as KLH-speciﬁc antibody-secreting cells (ASC) in
the circulation of vaccinees after oral KLH feeding (n = 9) or after
two subcutaneous KLH injections of nonprimed (n = 5) or orally
primed (n = 9) volunteers. The data are given as geometric means
of ASC/106 PBMC ± SEM.
PBMC; 75% of IgA-ISC were found to secrete IgA1 and 25%
IgA2.
3.2. KLH-Speciﬁc IgA-, IgG-, IgM-, IgA1-, and IgA2-ASC.
Before immunizations, no KLH-speciﬁc ASCs were found
in the circulation of any of the vaccinees. In the primed
group, none of the 9 volunteers had a response after oral
administration of KLH. After two subcutaneous injections,
9/9ofthesevolunteershadanASCresponsewithageometric
mean of 136 ASC/106 PBMC (Figure 2). In the nonprimed
group, 5/5 volunteers responded after two subcutaneous
KLHinjections witha geometric mean of60 ASC/106 PBMC
(Figure 2).
In orally primed volunteers, IgA predominated in 4/9
and IgG in 5/9 volunteers. In the nonprimed group, IgA
predominated in 2/5 and IgG in 3/5 volunteers.
KLH-speciﬁc IgA1- and IgA2-ASC were determined in
2/5 and 6/9 volunteers in the orally primed and nonprimed
groups, respectively. The mean percentage of KLH-speciﬁc
IgA1-ASCwas76%and86%inthesevolunteers,respectively.
3.3. The Expression of Homing Receptors on KLH-Speciﬁc
IgA-, IgG-, and IgM-ASC after Parenteral Vaccination. The
expressions of α4β7 integrin, L-selectin, and CLAon circulat-
ing KLH-speciﬁc ASC are shown in Figure 3. L-selectin was
f o u n dt ob ee x p r e s s e dm o r ef r e q u e n t l yt h a nα4β7 integrin
on KLH-speciﬁc ASC (P<. 001) in both the primed (P<
.01) and nonprimed (P<. 01) groups. Only 35% of KLH-
speciﬁc ASCexpressed α4β7 integrininthenonprimedgroup
and 50% in the primed group (Figure 3). L-selectin was
expressed by 80% and 89% of KLH-speciﬁc plasmablasts in
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Figure 3: The expression of the intestinal homing receptor, α4β7
integrin, the peripheral lymph node HR, L-selectin, and the skin
HR, CLA, on KLH-speciﬁc plasmablasts after two subcutaneous
KLH injections given to orally primed or nonprimed volunteers.
The data were calculated by counting the proportion ofHR positive
cells among all cells (the sum of HR positive and negative cells).
The data are given as arithmetic means of the percentage of ASC
expressingthegivenreceptor ±SD.Thenumbersofvolunteersfrom
whom the data were pooled are indicated under each bar.
nonprimed and primed groups, respectively. CLA expression
was determined from only three volunteers (Figure 3). The
results on α4β7 integrin- and L-selectin- expressions indicate
a nonintestinal, systemic homing proﬁle.
No major diﬀerences were seen in the homing proﬁles
between the cells secreting IgA, IgG, and IgM (data not
shown).
The sum of percentages of cells expressing the various
HR exceeded 100% in all patients with data available from
both α4β7 integrin and L-selectin. The sum varied between
105.5–149.4% thus suggesting that some cells were at least
double positive, that is, expressed more than one HR. This
phenomenon is suggested also by the height of the columns
in Figure 3.
4.Discussion
Immune responses are not evenly distributed in the body,
but, instead, activated lymphocytes are guided to those
tissues where their speciﬁc antigen is expected to be encoun-
tered [13]. The immune system decides on these sites on
the basis of where the new antigen was ﬁrst encountered;
each pathogen has a typical environmental locus and route
of transmission. Consequently, upon new encounters, the
pathogen tends to use the same route of invasion. Thus
it is advantageous to concentrate the immune response at
that site. In cancer vaccines, the eﬀector cells should be
guided to the area where the cancer has originated or spread;
with mucosal cancers, a mucosal homing proﬁle, and with
nonmucosal cancers, a systemic homing proﬁle appears as
to be most advantageous. The present study describes theClinical and Developmental Immunology 5
homing proﬁle of the immune response to KLH, a protein
carrier in numerous promising cancer vaccine candidates.
These data should be applicable to all KLH-conjugated
cancervaccines.TheeﬀectofpossibleoralprimingwithKLH
was explored at the same time.
Results from early clinical trials for idiotype vaccines
suggested that both humoral and cellular immune responses
may be independently associated with tumor regression and
improved progression-free survival [7]. We have previously
published data on KLH-speciﬁc T cell-mediated immunity
[10, 19] ;t h eh o m i n gp r o ﬁ l ew a sf o u n dt od e p e n do nt h e
site of antigen encounter, oral or parenteral [19]. In the
present study, KLH-speciﬁc B cell responses were exam-
ined in three diﬀerent settings. Consistently with previous
studies of B cells using the same feeding protocol for KLH
[10], no response manifested by ASC was elicited by oral
administration. However, in our previous studies [10, 19],
it has been shown that KLH-speciﬁc T cells are found after
oral KLH feeding, and, after a subsequent subcutaneous
administration, the B cell response is enhanced as compared
to a nonprimed group. The results of the present study
appear to be consistent with those ﬁndings, as indicated by
the geometric mean which appeared lower in the nonprimed
than in the orally primed group (60 versus 136 ASC/106
cells). The enhancement of B cell response resulting from
preceding oral feeding appears to oﬀer an opportunity of
utilization for cancer vaccines. However, the simultaneously
induced tolerance of T cells [10, 19] appears an undesired
consequence which may interfere with the idea of using oral
KLH priming as a means of enhancing immune response to
conjugated cancer vaccines.
In both this study and the previous studies, KLH
originated from two diﬀerent sources: “Calbiochem KLH”
for oral use versus “Paciﬁc Biomarine KLH” for parenteral
use. Although both preparations certainly contain the same
protein, they diﬀer in the grade of purity, possibly in
the assembly state of the protein, isoform proportion and
percentage of denatured versus native protein. Moreover, the
oral preparation was probably contaminated by endotoxin.
However, these factors presumably had no major impact on
the results of the present study where the immune responses
were measured with a highly puriﬁed KLH preparation, and
t h em a i nf o c u sw a so nt h eh o m i n go ft h eK L H - s p e c i ﬁ c
lymphocytes.
Thehoming oflymphocytesintovarioustissuesisguided
by the expression of HR and CCR on their surfaces [12,
13]. The combinations of these molecules act as traﬃcking
programmes imprinted on them during activation, targeting
their migration to speciﬁc tissues and microenvironments.
Dendritic cells in the tissues present the antigen to the lym-
phocytes in the tissues, simultaneously providing instruc-
tions for the expression of HR and CCR, that is, the homing
proﬁle [12, 13]. Dendritic cells from diﬀerent tissues give
diﬀerent instructions. The lymphocytes are generally guided
to travel back to the site of antigen encounter, but possibly
to certain other sites as well. Therefore, it would be useful
to identify the traﬃc k i n gp a t t e r n ss oa st ob ea b l et og u i d e
the cells to sites where they are desired. Paradoxically, the
majority of vaccines currently used against microbes are
given by systemic route, as injections at cutaneous sites,
although the majority of microbial pathogens gain access to
the body through the mucosal sites. With cancer vaccines, it
appears that the cells should be targeted to the site where the
tumour grows and its possible metastatic foci. In the present
study, a systemic homing proﬁle with high proportions
of L-selectin+ ASC and low proportions of integrin α4β7
+
ASC was revealed in both nonprimed and primed groups.
However, while L-selectin expressions were identical in the
two groups, the proportion of α4β7 integrin-expressing cells
appeared higher in the primed than in nonprimed volun-
teers. An analogous increased proportion of α4β7 integrin
in orally primed volunteers after a subsequent subcutaneous
booster immunization was found in our previous study on
Salmonella typhi Ty21a vaccines [28]. These data suggest a
slightly increased targeting to the intestine in the primed
group. This change appears undesirable for vaccines against
systemic cancers and adds to the negative eﬀects of oral
priming with KLH.
The homing proﬁle for KLH-conjugated cancer vaccines
is likely to prove similar to the homing proﬁle presented here
for parenteral KLH. The vaccine was only given to healthy
volunteers, no cancer patients were included. However, even
if cancer patients with immunosuppression are expected to
exhibit a less vigorous response, the disease will presumably
have no signiﬁcant impact on the homing proﬁles of the
immune eﬀector cells. The systemic homing proﬁle for
subcutaneous KLH indicated by the present study appears
to be the desirable type of HR proﬁle for responses against
nonmucosal cancers at systemic sites, thus encouraging
the development of this kind of parenterally administered
vaccines.
Abbreviations
ASC: antibody-secreting cell,
CCR: chemokine receptor,
HR: homing receptor,
ISC: immunoglobulin-secreting cell,
KLH: keyhole limpet haemocyanin.
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